4 June 2012 in Journal of Alzheimer’s Disease
OCon behalf of the AddNeuroMed Consortium
on behalf of the AddNeuroMed Consortium
+14
Alzheimer's disease (AD), like other dementias, is characterized by progressive neuronal loss and neuroinflammation in the brain. The peripheral leukocyte response occurring alongside these brain changes has not been extensively studied, but might in
19 September 2012 in Journal of Neuroscience
ATP-binding cassette transporter A1 (ABCA1) transporter regulates cholesterol efflux and is an essential mediator of high-density lipoprotein (HDL) formation. In amyloid precursor protein (APP) transgenic mice,Abca1deficiency increased amyloid deposition in the brain paralleled by decreased levels of Apolipoprotein E (ApoE). TheAPOEε4allele is the major genetic risk factor of sporadic Alzheimer's disease (AD). Here, we reveal the effect ofAbca1deficiency on phenotype in mice expressing human ApoE3 or ApoE4. We used APP/E3 and APP/E4 mice generated by crossing APP/PS1ΔE9 transgenic mice to human APOE3- and APOE4-targeted replacement mice and examinedAbca1gene dose effect on amyloid deposition and cognition. The results from two behavior tests demonstrate that lack of one copy ofAbca1significantly exacerbates memory deficits in APP/E4/Abca1−/+but not in APP/E3/Abca1−/+mice. The data for amyloid plaques and insoluble amyloid-β (Aβ) also show thatAbca1hemizygosity increases Aβ deposition only in APP/E4/Abca1−/+but not in APP/E3/Abca1−/+mice. Ourin vivomicrodialysis assays indicate thatAbca1deficiency significantly decreases Aβ clearance in ApoE4-expressing mice, while the effect ofAbca1on Aβ clearance in ApoE3-expressing mice was insignificant. In addition, we demonstrate that plasma HDL and Aβ42 levels in APP/E4/Abca1−/+mice are significantly decreased, and there is a negative correlation between plasma HDL and amyloid plaques in brain, suggesting that plasma lipoproteins may be involved in Aβ clearance. Overall, our results prove that the presence of functionalAbca1significantly influences the phenotype of APP mice expressing human ApoE4 and further substantiate therapeutic approaches in AD based on ABCA1–APOE regulatory axis.
1 January 2012 in NeuroImage
6 February 2013 in PLOS ONE
Chronic exposure to arsenic in drinking water, especially in utero or perinatal exposure, can initiate neurological and cognitive dysfunction, as well as memory impairment. Several epidemiological studies have demonstrated cognitive and learning deficits in children with early exposure to low to moderate levels of arsenic, but pathogenic mechanisms or etiology for these deficits are poorly understood. Since in vivo studies show a role for histone acetylation in cognitive performance and memory formation, we examined if prenatal exposure to arsenic causes changes in the epigenomic landscape. We exposed C57Bl6/J mice to 100 μg/L arsenic in the drinking water starting 1 week before conception till birth and applied chromatin immunoprecipitation followed by high-throughput massive parallel sequencing (ChIP-seq) to evaluate H3K9 acetylation pattern in the offspring of exposed and control mice. Arsenic exposure during embryonic life caused global hypo-acetylation at H3K9 and changes in functional annotation with highly significant representation of Krüppel associated box (KRAB) transcription factors in brain samples from exposed pups. We also found that arsenic exposure of adult mice impaired spatial and episodic memory, as well as fear conditioning performance. This is the first study to demonstrate: a) genome wide changes in H3K9 acetylation pattern in an offspring prenatally exposed to arsenic, and b) a connection between moderate arsenic exposure and cognitive impairment in adult mice. The results also emphasize the applicability of Next Generation Sequencing methodology in studies aiming to reveal the role of environmental factors, other than dietary restriction, in developmental reprogramming through histone modifications during embryonic development.
11 August 2010 in Journal of Alzheimer’s Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder where definite diagnosis can only be made postmortem, and for which the most promising peripheral markers of disease state and severity have been found in the cerebrospinal fluid. H
1 May 2018 in Journal of Neuroimmunology